Across TCGA pan-cancer cohorts, MIR629 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MIR629 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR629 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR629 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.
LIHC, BLCA, and READ are the cancer types where MIR629 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.